Show simple item record

dc.creatorWecker, M.
dc.creatorGilbert, Peter.
dc.creatorRussell, N.
dc.creatorHural, J.
dc.creatorAllen, Mary.
dc.creatorPensiero, M.
dc.creatorChulay, J.
dc.creatorChiu, Ya-Lin.
dc.creatorAbdool Karim, Salim Safurdeen.
dc.creatorBurke, D. S.
dc.date.accessioned2013-06-25T07:24:25Z
dc.date.available2013-06-25T07:24:25Z
dc.date.created2012
dc.date.issued2012-10
dc.identifier.citationWecker, M. et al. 2012. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19 (10) pp. 1651-1660.en
dc.identifier.issn1556-6811
dc.identifier.urihttp://dx.doi.org/10.1128/CVI.00258-12en
dc.identifier.urihttp://hdl.handle.net/10413/9189
dc.description.abstractOn the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, placebo-controlled clinical trials in healthy HIV-1-uninfected adults. Escalating doses of AVX101 or placebo were administered subcutaneously to participants in the United States and Southern Africa. Because of vaccine stability issues, the first trial was halted prior to completion of all dose levels and a second trial was implemented. The second trial was also stopped prematurely due to documentation issues with the contract manufacturer. Safety and immunogenicity were evaluated through assessments of reactogenicity, reports of adverse events, and assessment of replication-competent and Venezuelan equine encephalitis (VEE) viremia. Immunogenicity was measured using the following assays: enzyme-linked immunosorbent assay (ELISA), chromium 51 (51Cr)-release cytotoxic T lymphocyte (CTL), gamma interferon (IFN- y) ELISpot, intracellular cytokine staining (ICS), and lymphoproliferation assay (LPA). Anti-vector antibodies were also measured. AVX101 was well tolerated and exhibited only modest local reactogenicity. There were 5 serious adverse events reported during the trials; none were considered related to the study vaccine. In contrast to the preclinical data, immune responses in humans were limited. Only low levels of binding antibodies and T-cell responses were seen at the highest doses. This trial also highlighted the difficulties in developing a novel vector for HIV.en
dc.language.isoenen
dc.publisherAmerican Society for Microbiology.en
dc.subjectAIDS vaccines.en
dc.subjectAids (Disease)--Vaccines.en
dc.subject.otherHIV-1 subtype C gag vaccine (AVX101)en
dc.titlePhase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.en
dc.typePeer reviewed journal articleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record